Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yong-Gui Hong"'
Autor:
Ning Li, Tao Wu, Yong-Gui Hong, Yan-Zhen Guo, Yu-Feng Cheng, Yi-Jie Ma, Liang-Yu Bie, Dong-Hai Cui, Xiao-Hui Gao, Bing-Xu Tan, Bao-Sheng Li, Su-Xia Luo, Jun-Sheng Wang
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Anlotinib, a tyrosine kinase inhibitor, has shown encouraging anti-tumor activity in esophageal squamous cell carcinoma (ESCC). This study was designed to assess the efficacy and safety of anlotinib plus paclitaxel and cisplatin (
Externí odkaz:
https://doaj.org/article/ca63e027c0854a28ac12c5c52b9eebae
Autor:
Yan-Feng Zhang, Xiao-Bing Li, Yong-Gui Hong, Xiao-Ming Li, Wei-Min Liang, Zhi-Xin Zheng, Guang-Yi Yang, Yan-Yan Wen, Heng Cao, Wei-Long Wu, Wen-Zhong Su
Publikováno v:
Journal of Clinical Oncology. 41:366-366
366 Background: Neoadjuvant chemoradiation is associated with improved OS, DFS and pCR in patients (pts) with locoregional ESCC. Nevertheless, it is still needed to explore more tolerable preoperative regimen in ESCC. Anlotinib is a multi-targeted an
Autor:
Feng Wang, Junsheng Wang, Xiangrui Meng, Zhiquan Luo, Jin Xia, Yong-Gui Hong, Ping Lu, Yinghua Ji, Zheng-Zheng Shan, Qingxia Fan
Publikováno v:
Journal of Clinical Oncology. 41:384-384
384 Background: CAP 02 study (NCT03736863) is a single-arm phase 2 study to evaluate the efficacy and safety of camrelizumab plus apatinib (a VEGFR2 inhibitor) as second-line treatment in patients with advanced esophageal squamous cell carcinoma (ESC
Autor:
Xiuli Yang, Xiangrui Meng, Yong-Gui Hong, Zhiye Zhang, Jin Xia, Tao Wu, Yunfang Chen, Zheng-Zheng Shan, Qingxia Fan, Feng Wang
Publikováno v:
Journal of Clinical Oncology. 41:377-377
377 Background: PD-1 blockades combined with chemotherapy in first-line setting exhibited encouraging efficacy for patients with ESCC recently. However, the safety profile of conventional chemotherapy was still disappointing. Therefore, the chemother
Autor:
Ning Li, Tao Wu, Yong-Gui Hong, Yanzhen Guo, Yufeng Cheng, Baosheng Li, Junsheng Wang, Suxia Luo
Publikováno v:
Journal of Clinical Oncology. 41:376-376
376 Background: Paclitaxel combined with cisplatin regimen has been the standard of care as first-line therapy in advanced ESCC for almost two decades. PD-1 blockades combined with chemotherapy as first line setting exhibited superior efficacy for pa
Autor:
Yan-Feng Zhang, An-Lin Hao, Yong-Gui Hong, Xiao-Ming Li, Wei-Min Liang, Zhi-Xin Zheng, Guang-Yi Yang, Xiao-Feng Guo, Yan-Yan Wen, Heng Cao, Cheng Le, Hua-Jie Song, Wen-Zhong Su
Publikováno v:
Journal of Clinical Oncology. 40:e16015-e16015
e16015 Background: Neoadjuvant therapy could significantly improve survival for patients with locally advanced esophageal cancer. However, postoperative complications and recurrence are still urgent problems to be solved. Anlotinib was an effective s